Hi Donna,
Here is a study about Vidaza (azacitidine) before SCT. As you can see Vidaza treatment appears to be a valid therapeutic approach, but mainly in patients receiving Vidaza alone since allo-SCT in patients who required both Vidaza and chemotherapy had less satisfactory outcomes, possibly reflecting additional toxicity and/or more resistant disease.
The Vidaza alone patients were older (p =.025), had more often Int-2 and high IPSS (p=.013), poor cytogenetic IPSS (p<.001) and received more often NMA conditioning (p =.005) from an unrelated donor (p=.007) but they still did better.
http://ash.confex.com/ash/2011/webpr...aper36900.html
Many of the patients in the study had a more advanced disease than you have.
Kind regards
Birgitta-A